Increasing evidence has demonstrated the involvement of dysregulated long non-coding
RNAs (lncRNAs) in chemoresistance acting as potential oncogenes or tumor suppressors in …

OBJECTIVE: Ovarian cancer (OC) is a common tumor in women, and the development of
chemoresistance is the major obstacle to its treatment. Long non-coding RNAs (LncRNAs) …

The aim of this study was to explore the roles of the long noncoding RNA (lncRNA) urothelial
carcinoma-associated 1 (UCA1) on cisplatin resistance in ovarian cancer and the underlying …

Chemoresistance constitutes the major failing of clinical therapy for bladder cancer.
However, the molecular mechanisms involved in the chemoresistance of bladder cancer are …

Background Paclitaxel (PTX) occupies a considerable status in the chemotherapies of
breast cancer (BC), but the drug resistance keeps an obstructive factor of PTX treatment …

Background Chemoresistance contributes to treatment failure of gastric cancer (GC) patients
but the molecular mechanism of chemoresistance in GC is still unclear. Long-chain …

Paclitaxel is widely used as a first-line chemotherapeutic drug for patients with ovarian
cancer and other solid cancers, but drug resistance occurs frequently, resulting in ovarian …

Chemoresistance has become a major obstacle to effective retinoblastoma treatment. The
urothelial cancer-associated gene 1 (UCA1) is commonly considered an oncogene in …

Cisplatin resistance is still one of the main reasons for failure of clinical therapy for cervical
cancer. But the underlying molecular mechanisms involved in cisplatin resistance of cervical …

Cisplatin (DDP) resistance is a principal cause leading to poor prognosis in females
suffering from ovarian cancer (OC). Long non-coding RNA (lncRNA) has been shown to …